期刊文献+

4-羟基-2-(1H-吡唑-1-基)嘧啶-5-甲酸的合成工艺改进研究

Improvement of synthetic process of 4-hydroxy-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxylic acid
原文传递
导出
摘要 目的对4-羟基-2-(1H-吡唑-1-基)嘧啶-5-甲酸的合成工艺条件进行优化。方法以1-脒基吡唑盐酸盐和乙氧基甲叉基丙二酸二乙酯为起始原料,在三乙胺催化下环合得到中间体4-羟基-2-(1H-吡唑-1-基)嘧啶-5-甲酸乙酯,再经过氢氧化锂在四氢呋喃–水混合溶剂中水解得到目标化合物。结果合成了目标化合物,经MS、1H-NMR确证了结构,质量分数为99.5%,本合成工艺的总收率为87%。结论该合成工艺具有操作简单、反应条件温和、成本低、产率和纯度较高等优点,适合工业化生产。 Objective To optimize the synthetic process of 4-hydroxy-2-(1 H-pyrazol-1-yl)-pyrimidine-5-carboxylic acid. Methods 1-Amidinopyrazole hydrochloride and diethylethoxymethylenemalonate were used as starting materials to obtain the intermediate ethyl 4-hydroxy-2-(1 H-pyrazol-1-yl)pyrimidine-5-carboxylate through cyclization catalyzed by triethylamine. The title compound was obtained via hydrolysis by lithium hydroxide in mixed solvent of water and tetrahydrofuran. Results The target compound was synthesized and characterized by MS and 1 H-NMR. And the purity was 99.5%, and the total yield of this route was 87%. Conclusion The synthetic process has the advantages of simple operations, mild reaction conditions, low cost, high yield and purity, and is more suitable for industrial production.
作者 郭慧敏 高骏 段玉清 毕常芬 王绍杰 李祎亮 GUO Hui-min;GAO Jun;DUAN Yu-qing;BI Chang-fen;WANG Shao-jie;LI Yi-liang(Tianjin Technology Property Rights Exchange Co.,Ltd,Tianjin 300203,China;Shenyang Pharmaceutical University,Benxi 117004,China;Institute of Radiation Medicine,Chinese Academy of Medical Science & Peking Union Medical College,Tianjin 300192,China)
出处 《现代药物与临床》 CAS 2018年第12期3092-3095,共4页 Drugs & Clinic
基金 天津市自然科学基金青年项目(18JCQNJC09500) 中国医学科学院医学与健康科技创新工程项目(2016-I2M-3-022) 中央高校基本业务费项(3332018117)
关键词 脯氨酰羟化酶抑制剂 4-羟基-2-(1H-吡唑-1-基)嘧啶-5-甲酸 合成工艺 prolyl hydroxylase inhibitor 4-hydroxy-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxylic acid synthetic process
  • 相关文献

参考文献1

二级参考文献16

  • 1Stauffer M E, Fan T. Prevalence of anemia in chronic kidney disease in the United States [J]. PloS One, 2014, 9(1): e84943.
  • 2Arend M P, Flippin L A, Du X, et al. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin [P]. WO: 2004108681, 2004-12-16.
  • 3Forristal C E, Levesque J E Targeting the hypoxia- sensing pathway in clinical hematology [J]. Stem Cells TranslMed, 2014, 3(2): 135-140.
  • 4Provenzano R, Tumlin J, Zabaneh R, et al. Pharmacokinetics of oral FG-4592 to treat anemia in hemodialysis (Hd) patients (Pts) [J]. Am JKidney Dis, 2011, 57(4): B80.
  • 5Frohna P S, Milwee S, Pinkett J, et al. Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia [C]. San Francisco: Renal Week, 2007.
  • 6Chen X, Zheng X, Jiang J, et al. FG4592, a novel inhibitor of the prolyl hydroxylase of hypoxia-inducible factor (HIF-PH) elicited linear-exponential dose-response profile on plasma erythropoietin (EPO) levels [C]. Stockholm: 18th Congr Eur Hematol Assoc (EHA), 2013.
  • 7Yu K H, Chou J, Klaus S, et al. Comparable doses of FG-4592 have similar PK/PD in healthy Caucasian and Japanese subjects [J]. Nephrol Dial Transpl, 2013, 28: 362.
  • 8Besarab A, Hulter H N, Klaus S, et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [C]. Denver: Renal Week, 2010.
  • 9Besarab A, Provenzano R, Fishbane S, et al. FG-4592 oral hypoxia-inducible fator prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron [C]. Philadelphia: 44th Annu Meet Am Soc Nephrol (ASN), 2011.
  • 10Provenzano R, Goodkin D, Klaus S, et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to trrat anemia in hemodialysis patients [J]. Am JKidney Dis, 2011, 57(4): B80.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部